Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 36

Results For "LA"

8965 News Found

FDA approves AbbVie’s Upadacitinib for treatment of inflammatory bowel disease
Drug Approval | October 14, 2025

FDA approves AbbVie’s Upadacitinib for treatment of inflammatory bowel disease

Updated indication expands treatment options for patients with ulcerative colitis and Crohn’s disease when tumor necrosis factor (TNF) blockers are clinically inadvisable


Maverick Simulation installs 3D anatomage table at Safdarjung Hospital
Medical Device | October 14, 2025

Maverick Simulation installs 3D anatomage table at Safdarjung Hospital

The anatomage table is one of the most advanced 3D real-tissue–based anatomy visualization systems in the world


Moderna’s mRNA-4359 shows promising early results in resistant Melanoma at ESMO 2025
Clinical Trials | October 13, 2025

Moderna’s mRNA-4359 shows promising early results in resistant Melanoma at ESMO 2025

mRNA-4359 advances to phase 2 following encouraging results in checkpoint inhibitor-resistant Melanoma


Cadila launches allergy relief tablet Dlorfast-M
News | October 13, 2025

Cadila launches allergy relief tablet Dlorfast-M

Cadila Pharmaceuticals has introduced Dlorfast-M-Tablets as a dual-action therapy that targets two key pathways of allergic response


Roche to present latest cancer care data at ESMO 2025
Clinical Trials | October 13, 2025

Roche to present latest cancer care data at ESMO 2025

Roche will unveil the primary results from the phase III evERA Breast Cancer study evaluating giredestrant


Allergan Aesthetics launches SkinMedica’s reimagined packaging
Packaging | October 11, 2025

Allergan Aesthetics launches SkinMedica’s reimagined packaging

SkinMedica redefines luxury skincare with reimagined packaging and new HA5 hydra collagen water burst moisturizer


FDA approves Teva’s expanded indication for Uzedy for bipolar I disorder
Drug Approval | October 11, 2025

FDA approves Teva’s expanded indication for Uzedy for bipolar I disorder

UZEDY (risperidone) extended-release injectable suspension for subcutaneous use is indicated for use every one or two months for the treatment of schizophrenia in adults


Thermo Fisher launches new test to assess lung transplant rejection
News | October 10, 2025

Thermo Fisher launches new test to assess lung transplant rejection

New gene expression profiling test enhances precision in assessing lung transplant rejection and injury


Jubilant HollisterStier launches new sterile fill & finish line at its Spokane facility in US
News | October 10, 2025

Jubilant HollisterStier launches new sterile fill & finish line at its Spokane facility in US

The new line features advanced isolator technology to deliver enhanced sterility assurance, throughput and operational precision


Delhi High Court refuses to restrain Natco from manufacturing spinal muscular atrophy drug
News | October 10, 2025

Delhi High Court refuses to restrain Natco from manufacturing spinal muscular atrophy drug

The Court dismissed Swiss drugmaker Roche’s plea for interim injunction